Vivien E. Prise

Combretastatin A-4, an agent that displays potent and selective toxicity toward tumor vasculature.

G. Dark, S A Hill, Vivien E. Prise et al. · PubMed · 1997 · 624 citations

Vascular Shutdown, Tumor Biology, Oncology +16

Combretastatin A-4 phosphate as a tumor vascular-targeting agent: early effects in tumors and normal tissues.

G. M. Tozer, Vivien E. Prise, John Wilson et al. · PubMed · 1999 · 324 citations

Quantitative Autoradiography, Pathology, Tumor Biology +19

Mechanisms associated with tumor vascular shut-down induced by combretastatin A-4 phosphate: intravital microscopy and measurement of vascular permeability.

Gillian M. Tozer, Vivien E. Prise, John Wilson et al. · PubMed · 2001 · 288 citations

Pharmacotherapy, Biomedical Engineering, Tumor Biology +18

Evaluation of the anti‐vascular effects of combretastatin in rodent tumours by dynamic contrast enhanced MRI

Ross J. Maxwell, John Wilson, Vivien E. Prise et al. · NMR in Biomedicine · 2002 · 104 citations

Engineering, Oncologic Imaging, Tumour Blood Flow +17

Blood Vessel Maturation and Response to Vascular-Disrupting Therapy in Single Vascular Endothelial Growth Factor-A Isoform–Producing Tumors

Gillian M. Tozer, Simon Akerman, Neil A. Cross et al. · Cancer Research · 2008 · 103 citations · Full text